Marit Jalink, Chaja F Jacobs, Jahanzaib Khwaja, Dorothea Evers, Coty Bruggeman, Bruno Fattizzo, Marc Michel, Etienne Crickx, Quentin A A Hill, Ulrich Jaeger, Arnon P Kater, Anja B U Mäkelburg, Anouk Breedijk, Peter A W Te Te Boekhorst, Marlijn P A Hoeks, Masja de de Haas, Shirley P D'Sa, Josephine M I M I Vos
Autoimmune hemolytic anemia (AIHA) is a rare autoantibody-mediated disease. For steroid and/or rituximab-refractory AIHA, there is no consensus on optimal treatment. Daratumumab, a monoclonal antibody targeting CD38, could be beneficial by suppression of CD38+ plasmacells and thus autoantibody secretion. In addition, since CD38 is also expressed by activated T-cells, daratumumab may also act via immunomodulatory effects. We evaluated efficacy and safety of daratumumab monotherapy in an international retrospective study including 19 adult patients with heavily pretreated refractory AIHA...
March 20, 2024: Blood Advances